Genetically modified Zymomonas mobilis to utilize inorganic N source, methods and uses thereof are provided. The genetically modified Z. mobilis has a genome with the knockout of a locus ZMO1107 from Z. mobilis ZM4 could ferment inorganic N source.

Hybrid reverse transcriptases are provided that comprise a non-retroviral retrotransposon, or a fragment of the non-retroviral retrotransposon having reverse transcriptase activity, joined to a nucleic acid binding protein. Also provided are methods of using the hybrid reverse transcriptases to prepare a cDNA molecule library.

Provided are a bacterium having a 16S rRNA gene comprising a nucleotide sequence having 98.2% or more identity to the nucleotide sequence represented by SEQ ID NO: 1, and having an ability to degrade a target microorganism, a microbial preparation for degrading a target microorganism, comprising a bacterium (a1), and a method for degrading a target microorganism and a device for degrading a target microorganism using the same. Bacterium (a1) is a bacterium having a 16S rRNA gene comprising a nucleotide sequence having 90% or more identity to the nucleotide sequence represented by SEQ ID NO: 1, and having an ability to degrade a target microorganism.

The present invention relates to the technical field of microorganisms, and specifically to engineered microorganisms expressing acetoacetyl-CoA reductase variants and methods for increasing the proportion of 3-hydroxyhexanoic acid in PHA. The acetoacetyl-CoA reductase variants and their coding genes provided by the present invention can significantly increase the proportion of 3-hydroxyhexanoic acid in PHA produced by strains; the proportion of 3-hydroxyhexanoic acid in PHA produced by the engineered Ralstonia eutropha constructed utilizing the acetoacetyl-CoA reductase variants and their coding genes provided by the present invention is significantly increased, which provides new genes and strain resources for strains producing poly(3-hydroxybutyrate-co-3-10 the development of engineered hydroxyhexanoate) with high proportion of 3-hydroxyhexanoic acid.

The present invention relates to a novel bacterium Yersinia entomophaga MH96 as deposited at DSMZ on 4 May 2006 and designated accession no. DSM 1823 8. The present invention also relates to substances obtained or derived from Yersinia entomophaga MH96, which retain biopesticide activity. Methods for protecting a plant from pest infestation which include applying to the plant or its environment an effective amount of Yersinia entomophaga MH96 or a product delivered from the bacterium are also described.

Provided are a Bifidobacterium animalis subsp. lactis i797, a method for the separation and purification thereof, and a use thereof. The strain was deposited in the China General Microbiological Culture Collection Center on Aug. 20, 2019, wherein the deposit address is Building 3, No. 1 Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC NO. 18403. The Bifidobacterium animalis subsp. lactis i797 can adjust the balance of intestinal flora, improve stool characteristics, and has a better survival rate in simulated digestive juice; in addition, after being stored at 37 C., a relatively high temperature which is suitable for the growth of lactic acid bacteria, same can successfully control post-acidification.

The present disclosure provides compositions for improved Rhizobium-mediated transformation in transformation of recalcitrant plants, and methods of use thereof. Also provided are compositions and methods for Rhizobium-dependent delivery of heterologous proteins directly to plant cells.

A Ligilactobacillus animalis strain, which relates to the field of microbiotechnology. The L. animalis strain has been deposited in Guangdong Microbial Culture Collection Center on Oct. 13, 2022 at GDMCC NO.62867. The L. animalis strain HHP002 can inhibit the expression of cytokines mRNA in the human colon cancer cells, therefor inhibiting the generation of pro-inflammatory cytokines, and then inhibiting the further development of tumors, and can be applied to drugs for preventing and treating human colon cancer.

The present invention relates generally to medicine. More specifically the invention relates to the use of synergistic probiotic bacteria as intervention for health. In particular, the present invention provides a strain of Faecalibacterium prausnitzii and a bacterial strain which has one or more of the characteristics of: (i) being acetate producing, (ii) being lactate consuming and (iii) having the ability to be an electron acceptor, for use in the treatment or prevention of a disease associated with reduced butyrate levels or a disease associated with reduced or low numbers of Faecalibacterium prausnitzii bacteria.

Provided herein is an isolated Methanothermobacter microorganism that is (a) a microorganism of Methanothermobacter thermautotrophicus strain UC 120910, deposited on Dec. 21, 2010, with the American Type Culture Collection (ATCC) under ATCC Patent Deposit Designation No. PTA-11561, (b) a variant of the microorganism of Methanothermobacter thermautotrophicus strain UC 120910, or (c) a progeny of the microorganism of Methanothermobacter thermautotrophicus strain UC 120910, wherein the variant or progeny retains the phenotypic characteristics of the microorganism of Methanothermobacter thermautotrophicus strain UC 120910. Also provided herein is a substantially pure culture or monoculture comprising the Methanothermobacter microorganism of the disclosure. A system for converting electric power into methane, comprising a biological reactor having at least a cathode, an anode, a presently disclosed Methanothermobacter microorganism, water, and carbon dioxide, and method of using the system for converting electricity into methane are further provided herein.